Melanotan I (Afamelanotide, MT-1): A Research Review of the Linear α-MSH Analog and MC1R Agonist

Melanotan I (afamelanotide; MT-1; [Nle⁴,D-Phe⁷]-α-MSH; NDP-α-MSH) is a linear 13-residue synthetic analog of the endogenous pigmentary hormone α-melanocyte-stimulating hormone (α-MSH). Two substitutions — norleucine at position 4 and a D-phenylalanine at position 7 — convert a rapidly degraded native tridecapeptide into a protease-resistant, high-affinity agonist at the melanocortin-1 receptor (MC1R) on melanocytes. Research supplier catalogs list the compound under the labels "Melanotan 1," "MT-1," or "MT1 peptide"; the pharmaceutical literature calls the same molecule afamelanotide. This review clarifies that nomenclature, summarizes the melanocortin biology the peptide acts on, surveys the evidence by research domain, and distinguishes Melanotan I from its cyclic relatives Melanotan II and PT-141. All content is provided strictly for research reference.

By Peptide Insider Research Team · 11 min read · Last updated September 6, 2026

On this page

• Introduction
• Biological background: the melanocortin system and MC1R
• Compound structure and mechanism of action
• Evidence by research domain
• Melanotan I vs. Melanotan II vs. PT-141
• Limitations and research considerations
• Where to source for research
• Frequently asked research questions
• Works cited

Introduction

The melanotropins occupy an unusual place in peptide research. α-MSH was among the first peptide hormones sequenced, yet the native molecule is of limited laboratory utility because serum and tissue peptidases inactivate it within minutes. In 1980, Sawyer, Hruby and colleagues at the University of Arizona reported that replacing methionine-4 with norleucine and inverting the chirality of phenylalanine-7 produced an analog roughly 26-fold more potent than α-MSH in the frog-skin bioassay, with a duration of action described as "ultralong" — pigmentary effects persisted for days after a single exposure in vitro and in vivo [1]. A follow-up structure–activity series confirmed that the D-Phe⁷ substitution was the principal determinant of both potency and protease resistance [2].

The compound was licensed for development under the code Melanotan (later Melanotan I to distinguish it from the cyclic Melanotan II) and eventually received the international non-proprietary name afamelanotide [3]. It was approved by the European Medicines Agency in 2014 and by the U.S. Food and Drug Administration in 2019 as a subcutaneous implant for adults with erythropoietic protoporphyria (EPP), a rare photodermatosis [4,9]. Melanotan I therefore differs from most compounds in the research-peptide catalog: it is one of the few for which randomized controlled human data exist [4]. This review treats the compound as a laboratory reference material and sits alongside the site's review of the related melanocortin agonist PT-141 (bremelanotide).

Biological background: the melanocortin system and MC1R

The melanocortins — α-, β- and γ-MSH and adrenocorticotropic hormone (ACTH) — are all cleaved from the pro-opiomelanocortin (POMC) precursor and share the core tetrapeptide His-Phe-Arg-Trp that is necessary for receptor recognition [11]. They act on five G protein-coupled receptors, MC1R through MC5R, each coupled to adenylyl cyclase and cyclic AMP production. MC1R is expressed predominantly on epidermal melanocytes; MC2R is the ACTH receptor of the adrenal cortex and does not recognize α-MSH; MC3R and MC4R are central receptors involved in energy balance and autonomic regulation; MC5R is expressed in exocrine glands [11].

In the skin, ultraviolet radiation induces keratinocytes to release α-MSH and ACTH, which act in a paracrine fashion on melanocyte MC1R. The resulting cAMP signal activates protein kinase A and the transcription factor MITF, up-regulating tyrosinase and the related enzymes TYRP1 and DCT that drive eumelanin synthesis [11,12]. cAMP signaling also shifts melanogenesis away from the red-yellow pheomelanin toward the brown-black eumelanin, and has been reported to enhance nucleotide-excision repair and reduce apoptosis in UV-irradiated melanocytes independently of pigment production [12,13]. Loss-of-function MC1R variants — common in fair-skinned, red-haired individuals — blunt this cascade, which is the mechanistic basis for the interest in exogenous MC1R agonists as photoprotective agents [12,13].

Compound structure and mechanism of action

Structure. Melanotan I retains all thirteen residues of α-MSH, the N-terminal acetyl group and the C-terminal amide. Norleucine at position 4 removes the oxidation-prone methionine thioether while preserving the side-chain length; D-phenylalanine at position 7 sits within the His-Phe-Arg-Trp pharmacophore and both increases receptor affinity and blocks cleavage by endopeptidases that recognize the L-configured bond [1,2]. Radioligand binding studies in cells expressing individual human melanocortin receptors reported that [Nle⁴,D-Phe⁷]-α-MSH binds MC1R, MC3R, MC4R and MC5R with low-nanomolar affinity and is one of the reference agonists against which other analogs are characterized [10].

Mechanism. At MC1R the peptide behaves as a full agonist: cAMP accumulation, PKA activation, MITF induction and tyrosinase up-regulation follow the same route as for α-MSH, but with a prolonged receptor occupancy that produces melanin synthesis long after the ligand has cleared from plasma [1,9]. In cultured human melanocytes, the analog increased total melanin and raised the eumelanin:pheomelanin ratio, an effect that was reported even in cells from donors with low baseline pigmentation [5]. Studies of α-MSH and its analogs in melanocytes also reported reduced UV-induced hydrogen peroxide generation, fewer cyclobutane pyrimidine dimers and less apoptosis, findings attributed to cAMP-dependent enhancement of DNA repair rather than to melanin shielding alone [12,13].

Pharmacokinetic character. Early human pharmacokinetic work reported that the plasma half-life of Melanotan I is short — on the order of an hour or less — while the pigmentary response develops over days and persists for weeks, a dissociation consistent with the peptide acting as a trigger for a slow transcriptional program rather than requiring sustained receptor occupancy [8,9]. That mismatch is why the pharmaceutical form was developed as a controlled-release implant [9].

Evidence by research domain

Melanotan I is distinctive among research peptides in that the evidence base runs from bioassay pharmacology through randomized phase 3 trials. The table below summarizes the principal domains and the maturity of the evidence in each; details follow.

Receptor pharmacology and structure–activity relationships

The original 1980 report established the two features that define the compound: greatly increased potency and resistance to inactivation. In the frog-skin assay, [Nle⁴,D-Phe⁷]-α-MSH darkened skin at concentrations more than an order of magnitude below those required for α-MSH, and the darkening persisted after washout [1]. The 1982 structure–activity series compared a family of position-4 and position-7 analogs and reported that the D-Phe⁷ substitution alone accounted for most of the gain in potency and for resistance to serum enzymes [2]. Radioligand competition studies later placed the analog among the highest-affinity agonists at each of the four α-MSH-responsive receptor subtypes, which is why it remains a standard reference ligand in melanocortin receptor assays [10].

Melanocyte biology and DNA-repair signaling

In cultured human melanocytes, Hunt and colleagues reported that the analog increased eumelanin content and shifted the eumelanin:pheomelanin ratio upward [5]. Separately, Böhm and co-workers reported that α-MSH reduced UV-induced apoptosis and the formation of cyclobutane pyrimidine dimers in melanocytes, with the protective effect linked to MC1R signaling and cAMP [12]. Abdel-Malek and colleagues extended the observation to short α-MSH-derived tetrapeptide analogs, reporting reduced UV-induced hydrogen peroxide and enhanced DNA-damage repair, and proposed MC1R agonism as a melanoma-prevention strategy worth investigation [13]. These studies form the mechanistic rationale for the photoprotection work in volunteers.

Pigmentation and photoprotection in volunteers

Levine and colleagues reported in 1991 that the peptide induced measurable skin darkening in fair-skinned volunteers even at sites shielded from UV, demonstrating that the pigmentary response is receptor-driven rather than UV-dependent [6]. Dorr and colleagues subsequently reported that combining the analog with controlled solar-simulated UV exposure increased tanning and reduced the number of epidermal sunburn cells relative to UV alone [7]. Barnetson and colleagues reported that treated volunteers showed higher melanin density and fewer thymine dimers and sunburn cells after standardized UV challenge [15]. The peptide has therefore been studied as a systemic photoprotective agent rather than as a cosmetic — a distinction that matters for how the research literature should be read.

Erythropoietic protoporphyria and other photodermatoses

EPP is a rare inherited disorder in which accumulated protoporphyrin IX causes acute phototoxic pain within minutes of light exposure. Langendonk and colleagues reported in the New England Journal of Medicine two randomized, placebo-controlled phase 3 trials in which afamelanotide implants were associated with longer pain-free time in direct sunlight and improved quality-of-life scores [4]. A long-term observational study of 115 Swiss and Italian patients reported sustained effects and a stable safety profile over multiple years of follow-up [16]. In solar urticaria, an open-label pilot study reported a reduced response to UV provocation [17], and in nonsegmental vitiligo a randomized trial reported faster and more extensive repigmentation with afamelanotide plus narrowband UV-B than with phototherapy alone [18]. Regulatory reviews and pharmacokinetic summaries of the approved implant are available for readers who need the clinical development history [3,9,19].

Safety pharmacology

Adverse events reported in the controlled EPP trials included nausea, headache, flushing and darkening of pre-existing nevi [4,16]. Separately, public-health surveillance in the United Kingdom documented the circulation of unlicensed "melanotan" products of uncertain identity and purity, and highlighted the risk that such products may be mislabeled or contaminated — an observation that reinforces the importance of analytical verification for any laboratory working with the compound [14].

Melanotan I vs. Melanotan II vs. PT-141

The "Melanotan" label covers two chemically different peptides, and a third compound — PT-141 — is a direct derivative of the second. Conflating them is the most common error in secondary sources.

Melanotan I vs. Melanotan II

Melanotan II was designed to be a smaller, cyclic, more conformationally constrained agonist. In a pilot phase 1 study, Dorr and colleagues reported that it produced pigmentation but also nausea, stretching and yawning, and spontaneous penile erections — central effects attributed to MC3R/MC4R activation that the linear Melanotan I does not share to the same degree [20]. The serendipitous erection finding led to the development of PT-141 as a separate compound. Melanotan I, by contrast, has been characterized predominantly through its MC1R-mediated pigmentary and photoprotective actions [3,6].

Melanotan I vs. PT-141

PT-141 (bremelanotide) is the free-acid metabolite of Melanotan II and is discussed in detail in the site's PT-141 research review. It shares the His-D-Phe-Arg-Trp pharmacophore with Melanotan I but differs in size, ring structure and receptor weighting; the two compounds are studied in largely non-overlapping research domains.

Limitations and research considerations

• Nomenclature confusion. Catalog labels ("Melanotan," "MT-1," "MT1," "MT2") do not reliably distinguish the linear and cyclic compounds. Laboratories should confirm identity by mass spectrometry — the ~620 g/mol difference between Melanotan I and Melanotan II is unambiguous on MS [1,20].
• Purity and identity of research-grade material. Surveillance of unregulated products has reported mislabeling and uncertain purity [14]. HPLC purity and MS identity data should accompany any research lot; see the site's supplier evaluation guide.
• Receptor non-selectivity. Although MC1R is the target of interest in pigmentation research, the peptide also binds MC3R, MC4R and MC5R at nanomolar affinity [10]; experiments attributing effects to MC1R require receptor-null controls or selective antagonists.
• Formulation dependence. The pharmaceutical evidence derives from a controlled-release implant [4,9]. Findings from that formulation do not transfer directly to lyophilized peptide reconstituted in the laboratory, where the short plasma half-life dominates exposure [8].
• Species differences. Frog and rodent MC1R pharmacology differs from human MC1R, and mouse coat-color models do not reproduce the human epidermal melanin unit; results should be interpreted within the model used [1,11].
• Handling. Like other tryptophan-containing peptides, Melanotan I is light-sensitive; lyophilized material is typically stored frozen and protected from light, and reconstituted solutions are used promptly. Consult supplier certificates of analysis for lot-specific stability data.

Where to source for research

Melanotan I is listed by several research-peptide suppliers as a lyophilized powder, typically at 10 mg per vial, under the labels "Melanotan 1" or "MT-1." Because the literature explicitly documents mislabeled and impure melanotan products in unregulated channels [14], lot-specific HPLC purity and mass-spectrometric identity confirmation are the two documents a laboratory should insist on. The following suppliers list the compound for research use:

• Short Chain Aminos — lists Melanotan I alongside other melanocortin analogs with per-lot certificates of analysis; see the Peptide Insider supplier review.
• BioPep — catalogs research-grade Melanotan I with third-party purity testing; reviewed here.
• Catalyst Research — offers Melanotan I as a laboratory reference material with published analytical documentation; reviewed here.
• Apex Research Services — supplies Melanotan I for research applications with lot-traceable specifications; reviewed here.

All four are listed in the Peptide Insider suppliers directory. Availability is noted for research reference only; none of these listings constitute a recommendation for any use outside a laboratory setting.

Frequently asked research questions

Is Melanotan I the same as afamelanotide?

Yes. Melanotan I, MT-1 and afamelanotide are the same molecule: [Nle⁴,D-Phe⁷]-α-MSH, a linear 13-residue analog of α-MSH first reported in 1980. "Melanotan I" is the original development code and the label used in research catalogs; "afamelanotide" is the international non-proprietary name assigned during pharmaceutical development [1,3].

What is the difference between Melanotan I and Melanotan II?

Melanotan I is a linear tridecapeptide (~1,647 g/mol) that retains the full α-MSH backbone. Melanotan II is a cyclic heptapeptide (~1,024 g/mol) built on the truncated 4–10 core with a lactam bridge. Melanotan II is less receptor-selective and produced central effects — nausea, yawning, erections — in a phase 1 study that are not characteristic of Melanotan I [1,20].

What receptor does Melanotan I act on?

Its principal target is the melanocortin-1 receptor (MC1R), a G_s-coupled receptor on melanocytes whose activation raises cAMP, activates MITF and up-regulates tyrosinase. Binding studies also report nanomolar affinity at MC3R, MC4R and MC5R, so it is not MC1R-selective in the strict pharmacological sense; it has no activity at the ACTH receptor MC2R [10,11].

Why is Melanotan I more potent than α-MSH?

Two substitutions account for the difference. D-phenylalanine at position 7 sits inside the His-Phe-Arg-Trp pharmacophore, increasing receptor affinity and blocking endopeptidase cleavage; norleucine at position 4 removes the oxidizable methionine. Together they produced roughly 26-fold greater potency and an "ultralong" duration of pigmentary activity in the original frog-skin bioassay [1,2].

What has Melanotan I been studied for in humans?

The largest body of controlled data concerns erythropoietic protoporphyria, in which randomized phase 3 trials of the afamelanotide implant reported longer pain-free sun exposure [4]. Smaller studies have reported increased melanin density and reduced UV-induced DNA damage in volunteers, reduced UV sensitivity in solar urticaria, and enhanced repigmentation in vitiligo combined with phototherapy [6,7,15,17,18].

Does Melanotan I protect DNA from UV damage?

Laboratory studies report that MC1R agonism by α-MSH and its analogs reduces UV-induced cyclobutane pyrimidine dimers, hydrogen peroxide generation and apoptosis in cultured melanocytes, effects attributed to cAMP-dependent enhancement of DNA repair. Volunteer studies reported fewer thymine dimers and sunburn cells after UV challenge. These are research observations, not established protective claims [12,13,15].

How should Melanotan I be stored in the laboratory?

Supplier documentation generally recommends storing lyophilized Melanotan I frozen and protected from light, because the tryptophan residue is photosensitive and the peptide, like most lyophilized peptides, is hygroscopic. Reconstituted solutions are typically prepared fresh and kept cold. Lot-specific stability data should be taken from the supplier's certificate of analysis rather than generic guidance.

Works cited

1. Sawyer TK, Sanfilippo PJ, Hruby VJ, et al. 4-Norleucine, 7-D-phenylalanine-alpha-melanocyte-stimulating hormone: a highly potent alpha-melanotropin with ultralong biological activity. Proc Natl Acad Sci U S A. 1980;77(10):5754–5758. doi:10.1073/pnas.77.10.5754. PMID 6777774.
2. Sawyer TK, Hruby VJ, Darman PS, Hadley ME. Comparative biological activities of highly potent active-site analogues of alpha-melanotropin. J Med Chem. 1982;25(9):1022–1027. doi:10.1021/jm00351a004. PMID 6982339.
3. Hadley ME, Dorr RT. Melanocortin peptide therapeutics: historical milestones, clinical studies and commercialization. Peptides. 2006;27(4):921–930. doi:10.1016/j.peptides.2005.01.029. PMID 16412534.
4. Langendonk JG, Balwani M, Anderson KE, et al. Afamelanotide for erythropoietic protoporphyria. N Engl J Med. 2015;373(1):48–59. doi:10.1056/NEJMoa1411481. PMID 26132941.
5. Hunt G, Todd C, Kyne S, Thody AJ. Nle4DPhe7 alpha-melanocyte-stimulating hormone increases the eumelanin:phaeomelanin ratio in cultured human melanocytes. J Invest Dermatol. 1995;104(1):83–85. doi:10.1111/1523-1747.ep12613565. PMID 7798647.
6. Levine N, Sheftel SN, Eytan T, et al. Induction of skin tanning by subcutaneous administration of a potent synthetic melanotropin. JAMA. 1991;266(19):2730–2736. PMID 1658407.
7. Dorr RT, Ertl G, Levine N, et al. Effects of a superpotent melanotropic peptide in combination with solar UV radiation on tanning of the skin in human volunteers. Arch Dermatol. 2004;140(7):827–835. doi:10.1001/archderm.140.7.827. PMID 15262693.
8. Ugwu SO, Blanchard J, Dorr RT, et al. Skin pigmentation and pharmacokinetics of melanotan-I in humans. Biopharm Drug Dispos. 1997;18(3):259–269. PMID 9113347.
9. Minder EI, Barman-Aksoezen J, Schneider-Yin X. Pharmacokinetics and pharmacodynamics of afamelanotide and its clinical use in treating dermatologic disorders. Clin Pharmacokinet. 2017;56(8):815–823. doi:10.1007/s40262-016-0501-5. PMID 28063031.
10. Schiöth HB, Muceniece R, Wikberg JE, Chhajlani V. Characterisation of melanocortin receptor subtypes by radioligand binding analysis. Eur J Pharmacol. 1995;288(3):311–317. doi:10.1016/0922-4106(95)90043-8. PMID 7774675.
11. Cone RD. Studies on the physiological functions of the melanocortin system. Endocr Rev. 2006;27(7):736–749. doi:10.1210/er.2006-0034. PMID 17077189.
12. Böhm M, Wolff I, Scholzen TE, et al. alpha-Melanocyte-stimulating hormone protects from ultraviolet radiation-induced apoptosis and DNA damage. J Biol Chem. 2005;280(7):5795–5802. doi:10.1074/jbc.M406334200. PMID 15569680.
13. Abdel-Malek ZA, Kadekaro AL, Kavanagh RJ, et al. Melanoma prevention strategy based on using tetrapeptide alpha-MSH analogs that protect human melanocytes from UV-induced DNA damage and cytotoxicity. FASEB J. 2006;20(9):1561–1563. doi:10.1096/fj.05-5655fje. PMID 16723376.
14. Evans-Brown M, Dawson RT, Chandler M, McVeigh J. Use of melanotan I and II in the general population. BMJ. 2009;338:b566. doi:10.1136/bmj.b566. PMID 19224885.
15. Barnetson RS, Ooi TK, Zhuang L, et al. [Nle4-D-Phe7]-alpha-melanocyte-stimulating hormone significantly increased pigmentation and decreased UV damage in fair-skinned Caucasian volunteers. J Invest Dermatol. 2006;126(8):1869–1878. doi:10.1038/sj.jid.5700317. PMID 16763547.
16. Biolcati G, Marchesini E, Sorge F, Barbieri L, Schneider-Yin X, Minder EI. Long-term observational study of afamelanotide in 115 patients with erythropoietic protoporphyria. Br J Dermatol. 2015;172(6):1601–1612. doi:10.1111/bjd.13598. PMID 25494545.
17. Haylett AK, Nie Z, Brownrigg M, Taylor R, Rhodes LE. Systemic photoprotection in solar urticaria with α-melanocyte-stimulating hormone analogue [Nle4-D-Phe7]-α-MSH. Br J Dermatol. 2011;164(2):407–414. doi:10.1111/j.1365-2133.2010.10104.x. PMID 20969564.
18. Grimes PE, Hamzavi I, Lebwohl M, Ortonne JP, Lim HW. The efficacy of afamelanotide and narrowband UV-B phototherapy for repigmentation of vitiligo. JAMA Dermatol. 2013;149(1):68–73. doi:10.1001/2013.jamadermatol.386. PMID 23407924.
19. Fabrikant J, Touloei K, Brown SM. A review and update on melanocyte stimulating hormone therapy: afamelanotide. J Drugs Dermatol. 2013;12(7):775–779. PMID 23884489.
20. Dorr RT, Lines R, Levine N, et al. Evaluation of melanotan-II, a superpotent cyclic melanotropic peptide in a pilot phase-I clinical study. Life Sci. 1996;58(20):1777–1784. doi:10.1016/0024-3205(96)00160-9. PMID 8637402.

Explore related compounds: PT-141 (bremelanotide) · GHK-Cu · Semax (ACTH analog) · Selank · Epithalon